Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models

Fig. 2

The combination of ALRN-6924 and chemotherapeutic agents synergistically inhibit cell proliferation in vitro. a Cells were seeded in 96-well plates at a density of 5000–10,000 cells per well then treated for 72 h with vehicle, ALRN-6924, paclitaxel, eribulin, or combination of each. Effect on cell growth was determined using the SRB assay. IC50 values were calculated using GraphPad Prism software. b Combination indices were calculated using the Chou-Talalay method with a CI < 1 indicating synergistic activity. c MCF-7 colony formation assay treated for 14 days with either vehicle, ALRN-6924, paclitaxel, or combination of ALRN-6924 and paclitaxel. Total colony area was measured by using NIH ImageJ software. Mean ± SD (n = 2) values are shown

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us